Watch ABUS. Know when insiders buy.
One email the day a filing lands. Free.
ABUS
Arbutus Biopharma Corp
4.18
−0.15 −3.46%
USD · close Oct 21
A free account adds a watchlist, alerts when insiders, Congress or short sellers move on your tickers, and a morning brief. Sign up
Work order
44
WATCH · shorts 44
Insiders, 90 days
0
no open-market filings in 90 days
Congress, 90 days
0 / 0
no disclosures naming it
Big money
0 / 15
none of the tracked funds disclose it
Calls on record
0
nobody we score has called it yet
MKT CAP $827MP/E 5.3DIV YIELD —FCF YIELD —REV TTM $181.7M +1078.8%NET INCOME $153.1MNET CASH $19.2M52W 3.67 – 5.22SEC XBRL · TTM TO Invalid Date
Financials
By quarter
| Period | Revenue | YoY | Gross margin | Operating income | Net income | YoY | EPS | Op. cash flow | Capex | Free cash flow | Filed |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Q2 2026 · Jun 30 | $1M | −90.6% | — | −$6M | −$5.1M | −303.8% | -0.03 | −$6M | — | — | Aug 12 |
| Q1 2026 · Mar 31 | $179.1M | +10054.5% | — | $168.9M | $169.7M | — | 0.87 | −$8.1M | — | — | Aug 12 |
| Q4 2025 · Dec 31derived | $1.1M | −33.2% | — | −$5.3M | −$3.8M | — | -0.01 | −$4.7M | $0 | −$4.7M | Mar 23 |
| Q3 2025 · Sep 30 | $529K | −60.5% | — | −$8.7M | −$7.7M | — | -0.04 | −$5.8M | $0 | −$5.8M | Nov 13 |
| Q2 2025 · Jun 30 | $10.7M | +522.2% | — | $1.5M | $2.5M | — | 0.01 | −$15.7M | $0 | −$15.7M | Aug 12 |
| Q1 2025 · Mar 31 | $1.8M | +15.1% | — | −$25.7M | −$24.5M | — | -0.13 | −$13.4M | $0 | −$13.4M | Aug 12 |
| Q4 2024 · Dec 31derived | $1.6M | −26.6% | — | −$13.9M | −$12.5M | — | -0.07 | −$10.3M | $86K | −$10.4M | Mar 23 |
| Q3 2024 · Sep 30 | $1.3M | −71.3% | — | −$21.4M | −$19.7M | — | -0.10 | −$20.7M | $0 | −$20.7M | Nov 13 |
| Q2 2024 · Jun 30 | $1.7M | — | — | −$21.6M | −$19.8M | — | -0.11 | −$14.5M | $1K | −$14.5M | Nov 13 |
| Q1 2024 · Mar 31 | $1.5M | — | — | −$19.4M | −$17.9M | — | -0.10 | −$19.3M | $95K | −$19.4M | Nov 13 |
| Q4 2023 · Dec 31derived | $2.1M | — | — | −$20.7M | −$19.3M | — | -0.12 | −$17.3M | $0 | −$17.3M | Mar 27 |
| Q3 2023 · Sep 30 | $4.7M | — | — | −$21.6M | −$20.1M | — | -0.12 | −$21.8M | $32K | −$21.8M | Nov 6 |
By fiscal year
| Year | Revenue | Gross margin | Operating income | Net income | Net margin | EPS | Op. cash flow | Capex | Free cash flow | Buybacks | Dividends paid |
|---|---|---|---|---|---|---|---|---|---|---|---|
| FY2025 · to Dec 31 | $14.1M | — | −$38.2M | −$33.5M | -237.9% | -0.17 | −$39.6M | $0 | −$39.6M | — | — |
| FY2024 · to Dec 31 | $6.2M | — | −$76.3M | −$69.9M | -1133.0% | -0.38 | −$64.8M | $182K | −$65M | — | — |
| FY2023 · to Dec 31 | $18.1M | — | −$78.1M | −$72.8M | -401.6% | -0.44 | −$85.9M | $1M | −$86.9M | — | — |
| FY2022 · to Dec 31 | $39M | — | −$65.5M | −$69.5M | -178.0% | -0.46 | −$35.4M | $512K | −$35.9M | — | — |
| FY2021 · to Dec 31 | $11M | — | −$73.5M | −$76.2M | -693.9% | -0.83 | −$67.5M | $809K | −$68.3M | — | — |
| FY2020 · to Dec 31 | $6.9M | — | −$57.8M | −$63.7M | -922.0% | -1.00 | −$51.4M | $229K | −$51.7M | — | — |
Every number comes from Arbutus Biopharma Corp's own XBRL-tagged filings with the SEC, not a data vendor. Quarters marked derived are the fiscal year minus the three reported quarters, the same way every data provider computes Q4. Restated figures replace originals as later filings arrive.